FKBP1B

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, FKBP1B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FKBP1B data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher FKBP1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FKBP1B expression acts as an unfavorable survival marker.

CESC and STAD are the cancer types where FKBP1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
CESCOSMedianAll0.2610.798.00612view →
STADOSMedianAll0.2500.729.0286view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

FKBP1B–CESC (OS)

Kaplan–Meier survival curve for FKBP1B mutant vs wild-type samples in CESC.

Open the CESC breakdown →

Exploration